The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background Chronic kidney disease (CKD) is a major global public health problem, being
closely connected to cardiovascular disease. CKD involves an elevated thromboembolic risk …

Background There is a lack of clear benefit and a potential risk of bleeding with direct oral
anticoagulant (DOAC) use in chronic kidney disease (CKD) and dialysis patients with atrial …

A recent survey on the use of direct oral anticoagulants (DOACs) revealed that 43% of
patients with atrial fibrillation and renal impairment were potentially overdosed and had a …

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and its prevalence
increases with age. Few data are available about the clinical performance of direct oral …

Purpose We performed a systematic review and meta-analysis of randomized controlled
trials (RCTs) to evaluate the efficacy and safety of direct oral anticoagulation (DOAC) …

Atrial fibrillation (AF) and renal insufficiency often coexist and are increasingly prevalent with
advancing age. Both the risk of thromboembolic events and bleeding propensity are higher …

Background The risk of thromboembolic events is increased in patients with non-valvular
atrial fibrillation (NVAF) and renal impairment. The risk of bleeding events is increased if …

Background Reports suggest that renal decline is greater among patients with non-valvular
atrial fibrillation (NVAF) treated chronically with warfarin vs. some non-vitamin K antagonist …

Objective There is concern about long-term safety of direct oral coagulants (DOACs) in
clinical practice. Our aim was to investigate whether the introduction of DOACs compared …